Abstract
Introduction
Systemic mastocytosis (SM) is a rare hematological disorder characterized by an increase and focal accumulation of tissue mast cells (MC) in various organ-systems, predominantly skin, bone marrow (BM) and visceral organs. The type and degree of organ infiltration as well as subsequent organ damage represent the basis for the classification of SM into indolent SM
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(ISM), smoldering SM (SSM), SM with an associated clonal hematologic non-MC-lineage disease (SM-AHNMD), aggressive SM (ASM), and mast cell leukemia (MCL) [1] [2] [3] .
Advanced SM is associated with a poor prognosis, with a median overall survival (OS) of approximately 0.5, 2, and 3.5 years for patients with MCL, SM-AHNMD and ASM, respectively [3] . An acquired mutation in the receptor tyrosine kinase KIT, usually KIT D816V, is detectable in over 80-90% of all SM patients [4, 5] . AHNMD usually presents as a myeloid neoplasm such as chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPNu) or chronic eosinophilic leukemia (CEL) and frequently reflects the multilineage involvement of KIT D816V. The presence of additional mutations, most frequently TET2, SRSF2, ASXL1 or RUNX1, has recently been reported in a vast majority of patients with advanced SM [6] [7] [8] .
These mutations usually precede KIT D816V and are associated with a more dismal prognosis [7, [9] [10] [11] .
A thorough histological and immunohistochemical examination of the BM is recommended for the diagnosis and classification of SM. According to the World Health Organization (WHO) classification, diagnosis requires one major (multifocal compact MC infiltration) and one of four minor or three minor criteria, which include 1) atypical MC morphology (> 25% spindle shaped), 2) aberrant MC immunophenotype (expression of CD25/CD2), 3) activating mutations at codon 816 of KIT, predominantly KIT D816V, or 4) persistent elevation of baseline serum tryptase levels (> 20 ng/ml) [12] .
MC-related immunohistochemical markers, including tryptase and CD117 (KIT), represent powerful tools for the identification and quantification of MCs in the BM or other tissues, which may be more difficult when applying (only) conventional stains, like hematoxylin and
This article is protected by copyright. All rights reserved. eosin (H&E) or Giemsa, particularly in the presence of an AHNMD ( Figure 1 ) [13] .
Moreover, immunostaining enables detection of small but diagnostic compact MC infiltrates in some cases of SM. CD25 is a reliable marker for the differentiation between normal/reactive and neoplastic MCs because aberrant expression of this antigen is highly specific for SM and is seen in almost all patients and subtypes of SM [14] . The diagnosis of AHNMD is established by using WHO criteria, and is confirmed by evaluating peripheral blood (PB) and BM using additional immunological markers such as CD14 (monocytes), CD34 (progenitor/blast cells), CD61 (megakaryocytes), E-cadherin (erythroblasts) and 2D7
(basophils and immature eosinophils) [15] . In this study, we sought to retrospectively evaluate the concordance of diagnosis and classification of SM by comparing morphological, immunohistochemical and molecular analyses in two consecutively performed BM trephine biopsies in 65 patients with KIT D816V+ SM.
Materials and methods

Patients
In 
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Bone marrow histology/immunohistochemistry by RP
Conventional stains, such as Giemsa, Gömöri's silver impregnation and naphthol AS-D chloroacetate esterase were applied to all trephine specimens. Sections were immunostained using the avidin-biotin complex method with antibodies against various antigens associated with MCs (tryptase, CD25, and CD117), stem cells (CD34), myelomonocytic cells (myeloperoxidase, lysozyme, CD15, and CD68), megakaryocytes (CD61), erythroblasts (Ecadherin) and basophils/immature eosinophils (2D7) ( Table 1) .
For this analysis, SM and ASM were summarized because they can not be differentiated by morphologic findings in the BM but only by the presence or absence of characteristic clinical features (C-findings) which include cytopenia(s) with an absolute neutrophil count < 1 x 10 9 /L, hemoglobin < 10.0 g/dL and/or platelets < 100 x 10 9 /L, hepatomegaly with impaired liver function, palpable splenomegaly with signs of hypersplenism, malabsorption with significant hypoalbuminemia and/or significant weight loss > 10% over the last 6 months and osteolyses [1] .
KIT D816V and serum tryptase level
For the qualitative and quantitative assessment of KIT D816V at the RNA-level (expressed allele burden, EAB), allele-specific quantitative real-time polymerase chain reaction analysis (RQ-PCR) was performed in PB or BM as previously described [4] . The presence of KIT D816V mutations in BM trephine biopsies was investigated as previously described [16] .
Serum tryptase levels were measured by ImmunoCap Tryptase (Phadia Laboratory Systems, Uppsala, Sweden) and were available in 59/65 (91%) patients.
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Statistical analysis
All statistical analyses considered clinical and laboratory parameters obtained at time of diagnosis or first referral to our center that in most instances, coincided with time of BM biopsy and study sample collection. For categorical variables, two patient groups were compared with the exact Fisher test. P-values < 0.05 were considered significant. SPSS version 22.0.0 (IBM Corporation) were used for statistical analysis.
Results
Evaluation by RP
Final diagnoses by RP were SM (n = 27), (A)SM-AHNMD (n = 34), MCL (n = 3) and MCL-AHNMD (n = 1). AHNMD included CMML (n = 11), MDS/MPNu (n = 11), CEL (n = 5), myelodysplastic syndrome (MDS, n = 4), primary myelofibrosis (PMF, n = 1), acute myeloid leukemia (AML, n = 1), polycythemia vera (PV, n = 1) and chronic lymphocytic leukemia (CLL, n = 1). All patients with (A)SM/MCL-AHNMD fulfilled the major diagnostic criterion of multifocal dense infiltrates of MCs. Quantitative assessment of the extent of MC infiltration (tryptase, CD117, CD25) was reported in all patients (median 25%, range 5-90).
Concomitant reticulin fibrosis and eosinophilia was observed in 41/65 (64%) and 48/65 (74%) patients, respectively. KIT D816V mutational analysis was performed and positive in all 65 patients ( Table 2) . The serum tryptase level (normal value < 11.4 ng/ml) was elevated in 59/59 patients (median 132 ng/ml, range 12-1690).
Evaluation by LP
LP diagnosed SM in 50/65 (77%) patients: SM (n = 33), SM-AHNMD (n = 14) and MCL (n = 3). Diagnosis of AHNMD included CMML (n = 3), MDS (n = 3), PMF (n = 3), MDS/MPNu (n = 2), CEL (n = 1), PV (n = 1) and CLL (n = 1). MC infiltration was
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Characteristics of discordantly diagnosed patients
Patients who were initially misdiagnosed (by missing SM) by LP (n = 15) experienced a median delay of 11 months (range 0-61 months) before a second diagnostic biopsy was 
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Significant differences (P < 0.001) between LP and RP regarding misdiagnosis, missing of AHNMD, quantification of MCs, immunohistochemistry, performance of fibre staining and mutational analysis are summarized in Table 2 .
Discussion
In The performance or even recommendation for mutational testing for KIT D816V in correctly diagnosed SM was also unexpectedly low. Qualitative and quantitative assessment of KIT D816V is extremely helpful to establish a correct diagnosis of SM, particularly in cases with only ambiguous BM MC infiltration or puzzling morphological findings. In addition, it is also useful for monitoring of response to treatment through recently established, highly sensitive techniques, which allow the detection of KIT D816V at levels down to 0.01% [4, 5, 17] . In SM-AHNMD, the KIT D816V mutation is usually also identified in other lineages indicating SM-AHNMD as multilineage involvement of KIT D816V. The clinical
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consequences of non-diagnosed KIT D816V+ SM or SM-AHNMD are dismal considering the inferior prognosis of advanced SM on one side and the recently emerging positive results of targeted treatment towards KIT-dysregulated hematopoiesis with tyrosine kinase inhibitors, e.g. midostaurin (PKC412), or allogeneic stem cell transplantation (ASCT) on the other side [3, 19] .
The frequently unspecific symptoms in combination with organ dysfunction (e.g. cytopenia, impaired liver function, malabsorption) may explain the broad range of differential diagnoses, including reactive conditions and neoplasms [15] . The complex clinical picture of SM patients highlights that disease-typical symptoms, alone but even more importantly in combinations, such as anaphylaxis plus osteoporosis, cytopenia plus gastrointestinal symptoms, monocytosis plus eosinophilia or eosinophilia plus retroperitoneal lympadenopathy should more frequently lead to the routine estimation of serum tryptase levels and KIT D816V mutation status in PB prior to BM biopsy.
Obviously, one could argue that LP and RP should have analyzed the same biopsy and that at least in some of these patients, SM may just have developed shortly prior to the second biopsy. However, the interval between the two biopsies in three cases with incorrect diagnosis was less than 4 weeks and in all 9 patients with incorrect subclassification through missed AHNMD was only 1 to 8 months. All patients had to live with the incorrect diagnosis by LP, independently from the time interval between evaluation by LP and RP. Arguments that LP may have missed diagnosis due to low MC infiltration are counteracted by the fact that median BM MC infiltration in incorrectly diagnosed patients was 30% and advanced SM was diagnosed in 93% of patients. Several patients have even been treated for the incorrectly
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This article is protected by copyright. All rights reserved. (Fig. CD25) . The antibody 2D7 detects a basophil-related antigen and depicts a cell cluster in the immediate vicinity of a compact mast cell infiltrate (Fig. 2D7 ).
The final diagnosis could read as follows: ASM-HES. Altogether, this is a very challenging diagnosis and only possible after thorough immunohistochemical analysis. 
